352 related articles for article (PubMed ID: 1998959)
1. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
2. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Vallera DA
J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.
van Oosterhout YV; Preijers FW; Wessels HM; de Witte T
Cancer Res; 1992 Nov; 52(21):5921-5. PubMed ID: 1394218
[TBL] [Abstract][Full Text] [Related]
6. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
[TBL] [Abstract][Full Text] [Related]
7. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
Recht LD; Griffin TW; Raso V; Salimi AR
Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of ricin A chain immunotoxin activity by perhexiline on established and fresh leukemic cells.
Jaffrézou JP; Levade T; Kuhlein E; Thurneyssen O; Chiron M; Grandjean H; Carrière D; Laurent G
Cancer Res; 1990 Sep; 50(17):5558-66. PubMed ID: 2386962
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
10. Degradation of ricin A chain by endosomal and lysosomal enzymes--the protective role of ricin B chain.
Bilge A; Howell-Clark J; Ramakrishnan S; Press OW
Ther Immunol; 1994 Aug; 1(4):197-204. PubMed ID: 7584495
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.
Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC
Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246
[TBL] [Abstract][Full Text] [Related]
12. HeLa cell mutants resistant to epidermal growth factor ricin A-chain conjugate.
Banker D; Herschman HR
J Cell Physiol; 1989 Apr; 139(1):42-50. PubMed ID: 2785116
[TBL] [Abstract][Full Text] [Related]
13. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
14. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Frankel AE; Burbage C; Fu T; Tagge E; Chandler J; Willingham MC
Biochemistry; 1996 Nov; 35(47):14749-56. PubMed ID: 8942636
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
[TBL] [Abstract][Full Text] [Related]
16. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.
Griffin TW; Pagnini PG; Houston LL
J Biol Response Mod; 1987 Oct; 6(5):537-45. PubMed ID: 3500277
[TBL] [Abstract][Full Text] [Related]
18. Differences in cytotoxicity of native and engineered RIPs can be used to assess their ability to reach the cytoplasm.
Svinth M; Steighardt J; Hernandez R; Suh JK; Kelly C; Day P; Lord M; Girbes T; Robertus JD
Biochem Biophys Res Commun; 1998 Aug; 249(3):637-42. PubMed ID: 9731188
[TBL] [Abstract][Full Text] [Related]
19. Co-application of ricin A chain and a recombinant adenovirus expressing ricin B chain as a novel approach for cancer therapy.
Wang HB; Xia F; Ge J; Yin J; Tan LS; Zhang PD; Zhong J
Acta Pharmacol Sin; 2007 May; 28(5):657-62. PubMed ID: 17439722
[TBL] [Abstract][Full Text] [Related]
20. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
